Empagliflozin Found to Preserve Exercise Ability in Chronic Heart Failure
Empagliflozin was not found to affect the exercise ability of patients with chronic heart failure with reduced or preserved ejection fraction after 12 weeks of treatment.
Heart Failure
Racial Differences Seen With Hypertrophic Cardiomyopathy
Racial differences in disease expression and adverse clinical outcomes exist between black and white patients with hypertrophic cardiomyopathy.
Extracorporeal vs Conventional CPR for Out-of-Hospital Cardiac Arrest
Extracorporeal cardiopulmonary resuscitation (CPR) of patients experiencing out-of-hospital cardiac arrest was not found to be associated with increased survival when compared with conventional CPR.
Pulmonary Disease Can Predict All-Cause Hospitalization in HFpEF
In patients with heart failure with preserved ejection fraction, pulmonary disease may be an independent predictor of all-cause and heart failure hospitalizations.
Heart Failure-Exacerbating Medications Common After HF Hospitalization
Investigators sought to identify the patterns of heart failure (HF)-exacerbating medications used among older adults hospitalized for HF and to analyze factors for HF-exacerbating medication use.
IASD May Improve Pulmonary Vascular Function During Rest and Exercise in HF
The researchers sought to determine whether an interatrial shunt device would improve pulmonary artery function at rest and during exercise in patients without heart failure without lessening systemic blood flow.
Subcutaneous ICD Performance Similar With, Without Structural Heart Disease
Subcutaneous implantable cardioverter-defibrillator is a feasible option not only in patients without structural but also in a selected patient collective with structural heart disease.
Vericiguat Reduces Risk for Heart Failure Hospitalization, CV Death in HFrEF
Vericiguat (Merck and Bayer) reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure, according to new phase 3 data.
Benefits of Sacubitril/Valsartan Appear to Be Greater in Certain HFpEF Subgroups
Treatment with sacubitril/valsartan provides greater benefits in certain patients with HFpEF, according to analyses from the phase 3 PARAGON-HF trial.
Empagliflozin Reduces HF Hospitalization Risk Compared With Other Antidiabetic Agents
Treatment with empagliflozin, a SGLT2 inhibitor, was associated with reduced risk of hospitalization for heart failure.
Next post in AHA 2019
